In a recent study on ovarian cancer cell lines, Westhoff et al. (2014) demonstrated that when TSR is used in combination with the standard paclitaxel/cisplatin chemotherapy, it decreases Forkhead box M1 (FOXM1) gene expression besides showing an enhanced synergistic cytotoxicity in ascites cells from platinum-resistant patients. This evidence concerns the gene FOXM1 and ovarian carcinoma.